GlassScriptPhysician profile
Tyler Popil
NPI 1235638263
$1,743.01
in general payments reported to CMS, 2019-2025
23 companies · $738 in 2025
The $738 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2023: $36.52 · 2024: $788 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.69 | 2021-2025 | |
| Astellas Pharma US INC | $205.55 | 2024-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $107.46 | 2021-2025 | |
| Novo Nordisk INC | $89.66 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $86.69 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $76.61 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $73.70 | 2024-2025 | Eliquis |
| Lilly USA, LLC | $59.11 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $53.12 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.40 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $52.39 | 2021 | |
| Glaxosmithkline, LLC. | $50.51 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $39.36 | 2024-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $36.24 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.30 | 2021-2024 | Tradjenta, Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31.34 | 2024-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $21.58 | 2025 | Korlym |
| Lundbeck LLC | $19.64 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $17.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.75 | 2024 | Xifaxan |
| Painteq LLC | $14.48 | 2024 | Painteq |
| Amgen INC. | $13.58 | 2025 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.37 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Popil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.